Update on treatment of unresectable stage III NSCLC_Jeff Bradley, MD, FACR, FASTRO; #DDHO2021
Uncommon and emerging targets for NSCLC_Fadlo Khuri, MD; #DDHO2021
Andreas N. Saltos, MD; Moffitt Cancer Center; 5Live; #IASLC21
Narjust Duma, MD; University of Wisconsin-Madison, University of Wisconsin Carbone Cancer Center; 5Live; #IASLC21
Benjamin Besse, MD, PhD; Gustave Roussy Cancer Campus; 5Live; #IASLC21
Suresh Ramalingam, MD, FACP, FASCO; Winship Cancer Institute of Emory University; 5Live; #IASLC21
David Carbone, MD, PhD, FASCO; The Ohio State University Comprehensive Cancer Center; 5Live; #IASLC21
Suresh Ramalingam, MD, FASCO; Winship Cancer Institute Emory University 5Live #ASCO20
Key insights on Nivolumab + ipilimumab versus platinum-doublet chemotherapy as first-line treatment for advanced non-small cell lung cancer: Three-year update from CheckMate 227 Part 1.
Vivek Subbiah, MD The University of Texas MD Anderson Cancer Center 5Live #ASCO20
Key Insights on Intracranial activity of selpercatinib (LOXO-292) in RET fusion-positive non-small cell lung cancer (NSCLC) patients on the LIBRETTO-001 trial.
Roy Herbst, MD, PhD, FACP, FASCO; Yale Cancer Center 5Live #ASCO20
Key insights on Osimertinib as adjuvant therapy in patients (pts) with stage IB–IIIA EGFR mutation positive (EGFRm) NSCLC after complete tumor resection: ADAURA.
Natasha B. Leighl, MD, MMSc, FRCP, FASCO Princess Margaret Cancer Center, Toronto 5Live #ASCO20
Key Insights on CCTG BR.34: A randomized trial of durvalumab and tremelimumab +/- platinum-based chemotherapy in patients with metastatic (Stage IV) squamous or nonsquamous non-small cell lung cancer (NSCLC).
- Next Page